Whalesbook
Toh hua kya hai ki, Choice Institutional Equities naam ke ek analyst firm ne Park Medi World (PARKHOSP) ke stock par coverage shuru kiya hai. Aur unhone seedha 'BUY' rating de diya hai, saath mein target price bhi ₹320 set kiya hai. Ye analyst bol rahe hain ki stock abhi bhi 36% tak aur upar ja sakta hai.
Is confidence ka reason company ka expansion plan hai. Ye log apna hospital bed capacity 5 saal mein 3,960 beds se badha kar 10,000 beds se bhi zyada karne wale hain. Aur ye sab hoga kaise? Toh ye log ek super efficient model use kar rahe hain jisme per bed sirf ₹34 Lakh ka kharcha aayega, jabki competitors ₹80-100 Lakh kharch karte hain. Sabse important baat, ye poora expansion company apne internal paison se hi karegi, matlab shareholders ko koi naya share issue karke dilute nahi karengi. Plus, ye log thode distressed assets bhi kharidne ka soch rahe hain jisse fayde mein deal ho sake.
Waise stock pehle se hi accha performance de raha hai. Saal bhar mein 58.93% aur iss saal ab tak 56% gain kar chuka hai. Aur sector ki baat karein toh India mein healthcare ki demand zabardast hai. Aisi estimates hain ki around 2.4 million beds ki kami hai World Health Organization ke hisab se. Public mein health awareness badh rahi hai, log lambi zindagi jee rahe hain aur insurance bhi zyada ho raha hai. Isliye bade hospital chains bhi FY27 tak 14,500+ beds add karne ka plan bana rahi hain.
Ab aate hain thode 'but' par. Stock ka valuation dekhne mein kaafi mehnga lag raha hai. Jahaan analyst ka FY28E ke liye target EV/EBITDA multiple 18x hai, wahi stock ka current TTM Price-to-Earnings (P/E) ratio lagbhag 37.53x chal raha hai. Ab isko compare karo bade players se – Max Healthcare 65-71x P/E par hai, Fortis 58-67x par, aur Apollo Hospitals 59-73x P/E par trade ho rahe hain. Matlab, Park Medi World apne competitors ke comparison mein kafi premium par trade ho raha hai. Isse lagta hai ki market future earnings ko lekar thoda overconfident ho sakta hai.
Iske alawa bhi kuch risks hain. Analyst report khud keh rahi hai ki future target price achieve karne ke liye stock ke valuation mein girawat aani padegi. Company agar internal funds se expand kar rahi hai toh cash flows par pressure aa sakta hai aur execution bhi perfect hona chahiye. Pehle bhi dekha gaya hai ki government schemes par depend karne se payments delay hote hain, jisse working capital cycle slow ho jata hai. Aur toh aur, ye company mainly North India mein hi operate karti hai, jabki bade players ki nationwide presence aur diversified income streams hain. Analyst coverage bhi kam hai, sirf Choice Institutional Equities hi cover kar raha hai.
Toh overall scene yeh hai ki analyst ko stock mein potential dikh raha hai aur expansion plan bhi solid hai. Lekin high valuation aur execution risks ko nazarandaaz nahi kar sakte. Dekhna hoga ki company apne target ko kaise achieve karti hai aur valuation ko justify kar paati hai ya nahi. Sector toh growth mein hai hi!